- 47 次围观
产品图片
货号/SKU
NR-55632
货号/规格
EA
库存与交货期
3-8周
人民币价格
14000
试剂海关审批
A/B级风险物质只能直接使用人购买并持有实验室有效资质，其它询客服确认
国外采购
支持/部分限制一年内购买数量
厂牌
BEI Resources(ATCC)
产品基础信息
生物安全等级建议分类：美国、1
产品描述信息
NR-55632?? Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, R.1 Lineage with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells(Proteins)|SARS-Related Coronavirus 2|Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, R.1 Lineage with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells|-20°C or colder|BEI ResourcesAcknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, R.1 Lineage with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells, NR-55632.”|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
A recombinant form of the spike (S) glycoprotein from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), R.1 lineage was produced in human embryonic kidney HEK293 cells and purified by immobilized metal affinity chromatography. NR-55632 lacks the signal sequence and contains 1196 residues (ectodomain) of the SARS-CoV-2 spike glycoprotein; the recombinant protein was stabilized by substitution at the furin S1/S2 cleavage site (RRAR→GSAS; residues 682 to 685) and KV→PP mutations (residues 986 and 987; wild type numbering), and includes a T4 foldon trimerization domain, HRV3C protease cleavage site and C-terminal octa-histidine tag fused to an AviTag? BirA biotinylation acceptor sequence. NR-55632 includes W152L, E484K, D614G and G769V mutations in the S glycoprotein as compared to the SARS-CoV-2 reference sequence (GenPept: QHD43416). NR-55632 has a theoretical molecular weight of 139,600 daltons. The crystal structure for trimeric S glycoprotein from SARS-CoV-2 has been solved at 3.46 ? resolution (PDB: 6VSB).
The S glycoprotein mediates viral binding to the host angiotensin converting enzyme 2 (ACE2). This protein forms a trimer, and when bound to a host receptor allows fusion of the viral and cellular membranes. The R.1 lineage was predicted to have emerged around September 2020 and includes several key mutations of importance to the S glycoprotein: mutation W152L, which might reduce the effectiveness of neutralizing antibodies; mutation E484K, which has been identified in escape mutants from convalescent antisera, and is thought to play a role in the loss of antibody neutralizing activity; and mutation D614G, which is common to the current variants of interest and concern identified by the Centers for Disease Control and Prevention (CDC), was one of the first documented in the U.S. in the initial stages of the pandemic and demonstrates evidence of increasing virus transmissibility.
Each vial contains approximately 100 ?L of NR-55632 in 10 mM HEPES, pH 7, 150 mM NaCl and 2 mM ethylenediamine-tetraacetic acid (EDTA).
Additional information and tools are available at ViPR (Virus Pathogen Resource).
A recombinant form of the spike (S) glycoprotein from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), R.1 lineage was produced in human embryonic kidney HEK293 cells and purified by immobilized metal affinity chromatography. NR-55632 lacks the signal sequence and contains 1196 residues (ectodomain) of the SARS-CoV-2 spike glycoprotein; the recombinant protein was stabilized by substitution at the furin S1/S2 cleavage site (RRAR→GSAS; residues 682 to 685) and KV→PP mutations (residues 986 and 987; wild type numbering), and includes a T4 foldon trimerization domain, HRV3C protease cleavage site and C-terminal octa-histidine tag fused to an AviTag? BirA biotinylation acceptor sequence. NR-55632 includes W152L, E484K, D614G and G769V mutations in the S glycoprotein as compared to the SARS-CoV-2 reference sequence (GenPept: QHD43416). NR-55632 has a theoretical molecular weight of 139,600 daltons. The crystal structure for trimeric S glycoprotein from SARS-CoV-2 has been solved at 3.46 ? resolution (PDB: 6VSB).
The S glycoprotein mediates viral binding to the host angiotensin converting enzyme 2 (ACE2). This protein forms a trimer, and when bound to a host receptor allows fusion of the viral and cellular membranes. The R.1 lineage was predicted to have emerged around September 2020 and includes several key mutations of importance to the S glycoprotein: mutation W152L, which might reduce the effectiveness of neutralizing antibodies; mutation E484K, which has been identified in escape mutants from convalescent antisera, and is thought to play a role in the loss of antibody neutralizing activity; and mutation D614G, which is common to the current variants of interest and concern identified by the Centers for Disease Control and Prevention (CDC), was one of the first documented in the U.S. in the initial stages of the pandemic and demonstrates evidence of increasing virus transmissibility.
Each vial contains approximately 100 ?L of NR-55632 in 10 mM HEPES, pH 7, 150 mM NaCl and 2 mM ethylenediamine-tetraacetic acid (EDTA).
Additional information and tools are available at ViPR (Virus Pathogen Resource).
主要内容
此项目的每个订单数量限制为1.此商品每年可订购两次.此限制的订单将在发货前发送到NIAID批准.
来自严重急性呼吸综合征相关的冠状病毒2（SARS-COV-2），R.1谱系的重组形式，R.1谱系在人胚胎肾HEK293细胞中产生，并通过固定化金属亲和层析纯化. NR-55632缺少信号序列和
含有SARS-COV-2穗糖蛋白的1196个残基（Ectodomain）;通过在Furin S1 / S2切割位点（Rrar→GSAs;
残留物682至685）和KV→PP突变（残留物986和987;野生型编号），并且包括T4粘合三聚体化结构域，HRV3C蛋白酶切割位点和C-末端octa-组氨酸标签融合到
Avitag?Bira Biotinylation受体序列.与SARS-COV-2参考序列（Genpept： qhd43416 ）. NR-55632具有139,600道尔顿的理论分子量. SARS-COV-2的三聚糖蛋白的晶体结构已在3.46?分辨率（PDB： 6vsb ）中得到解决.
S糖蛋白介导与宿主血管紧张素转化酶2（ACE2）的病毒结合.该蛋白质形成三聚体，并且当与宿主受体结合时，允许融合病毒和细胞膜.预计R.1谱系左右9月2020年9月出现，包括对S糖蛋白的重要性的关键突变：突变W152L，这可能降低中和抗体的有效性;突变E484K，已在恢复突变体中识别来自康复抗血清的突变体，并且是
思想在抗体中和活性的丧失中发挥作用;和突变D614G，这对于疾病控制和预防中心（CDC）所识别的当前感兴趣的变异和涉及的突变是美国的第一个在大流行的初始阶段中的首次记录和表现出来
增加病毒传播性的证据.
每个小瓶在10mM Hepes，pH 7,150mM NaCl和2mM乙二胺 - 四乙酸（EDTA）中含有约100μl的NR-55632.
vipr （病毒病原体资源）提供了附加信息和工具.
厂牌介绍
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立，旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中，可以监控科学界对这些材料的访问和使用，并确保试剂的质量控制。
除了为传染病界提供材料外，BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势，包括安全存储、社区访问和分发；同时保护存款人的知识产权。只要有需要，BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月， ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料，包括由其他政府支持的研究项目存放的材料，将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中，涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
品牌标识
可能感兴趣的内容
2022-04-01
2022-04-01
2021-12-21
2024-09-22
2022-04-01
2024-10-20
2021-12-21
2022-03-31
2024-05-19
2022-04-01
2021-12-13
2024-06-25
2022-04-01